CN128 in iron overload in transfusion dependent thalassemia

Phase 2, open-label, single-arm trial of Tiralos in iron overload, sponsored by Hangzhou Zede Pharmaceutical Technology. Primary endpoints: Number of participants with adverse events, adverse reactions, severe adverse events and severe adverse reactions up to 52 weeks, Absolute Change in Weight at 52 weeks and 10 more. Started Jun 2022; status: completed.